ArticlePLoS neglected tropical diseases2015
Spot the difference-development of a syndrome based protein microarray for specific serological detection of multiple flavivirus infections in travelers.
Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Dengue in the Middle East and North Africa: A Systematic Review.PLoS neglected tropical diseases · 2016Pooled it
- Improved and customized dengue serodiagnostics through combined NS1/IgM testing and novel dual-cut-off IgG ELISA.PLoS neglected tropical diseases · 2026Article
- Dengue Fever Diagnosis: Performance Characteristics of Current Tests and Emerging Detection Technologies.Molecular diagnosis & therapy · 2026Review
- Estimating Zika Virus Seroprevalence in a Dengue Virus-Endemic Population: The Use of Blood Donors and Multiplex Serology to Monitor Arbovirus Outbreaks in the Dutch Caribbean.The Journal of infectious diseases · 2025Article
- Article
- One Health approach uncovers emergence and dynamics of Usutu and West Nile viruses in the Netherlands.Nature communications · 2025Article
- Usutu Virus Antibody Dynamics in Naturally Infected Blackbirds, the Netherlands, 2016-2018.Emerging infectious diseases · 2025Article
- Estimating the force of infection of four dengue serotypes from serological studies in two regions of Vietnam.PLoS neglected tropical diseases · 2024Article
- A species-independent lateral flow microarray immunoassay to detect WNV and USUV NS1-specific antibodies in serum.One health (Amsterdam, Netherlands) · 2024Article
- Article
- Serum antibody fingerprinting of SARS-CoV-2 variants in infected and vaccinated subjects by label-free microarray biosensor.Frontiers in immunology · 2024Article
- Countering Dengue infection in Bangladesh in the backdrop of current outbreak.New microbes and new infections · 2023Article
- Assessing West Nile virus (WNV) and Usutu virus (USUV) exposure in bird ringers in the Netherlands: a high-risk group for WNV and USUV infection?One health (Amsterdam, Netherlands) · 2023Article
- Serological Cross-Reactivity in Zoonotic Flaviviral Infections of Medical Importance.Antibodies (Basel, Switzerland) · 2023Review
- Evaluation of the use of alternative sample types for mosquito-borne flavivirus surveillance: Using Usutu virus as a model.One health (Amsterdam, Netherlands) · 2022Article
- Sero-epidemiological study of arbovirus infection following the 2015-2016 Zika virus outbreak in Cabo Verde.Scientific reports · 2022Article
- Recent Advances in Rapid and Highly Sensitive Detection of Proteins and Specific DNA Sequences Using a Magnetic Modulation Biosensing System.Sensors (Basel, Switzerland) · 2022Review
- Evidence of Infection with Zoonotic Mosquito-Borne Flaviviruses in Saltwater Crocodiles (Viruses · 2022Article
- Transplacental Zika virus transmission in ex vivo perfused human placentas.PLoS neglected tropical diseases · 2022Article
- Age-seroprevalence curves for the multi-strain structure of influenza A virus.Nature communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 10 institutions in 10 countries.
Funding
Abstract
backgroundThe family Flaviviridae, genus Flavivirus, holds many of the world's most prevalent arboviral diseases that are also considered the most important travel related arboviral infections. In most cases, flavivirus diagnosis in travelers is primarily based on serology as viremia is often low and typically has already been reduced to undetectable levels when symptoms set in and patients seek medical attention. Serological differentiation between flaviviruses and the false-positive results caused by vaccination and cross-reactivity among the different species, are problematic for surveillance and diagnostics of flaviviruses. Their partially overlapping geographic distribution and symptoms, combined with increase in travel, and preexisting antibodies due to flavivirus vaccinations, expand the need for rapid and reliable multiplex diagnostic tests to supplement currently used methods. GOAL: We describe the development of a multiplex serological protein microarray using recombinant NS1 proteins for detection of medically important viruses within the genus Flavivirus. Sera from clinical flavivirus patients were used for primary development of the protein microarray.
resultsResults show a high IgG and IgM sensitivity and specificity for individual NS1 antigens, and limited cross reactivity, even within serocomplexes. In addition, the serology based on this array allows for discrimination between infection and vaccination response for JEV vaccine, and no cross-reactivity with TBEV and YFV vaccine induced antibodies when testing for antibodies to other flaviviruses.
conclusionBased on these data, multiplex NS1-based protein microarray is a promising tool for surveillance and diagnosis of flaviviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.